|
KMID : 0988920220200010078
|
|
Intestinal Research
2022 Volume.20 No. 1 p.78 ~ p.89
|
|
|
Effectiveness of administering zinc acetate hydrate to patients with inflammatory bowel disease and zinc deficiency: a retrospective observational two-center study
|
|
Sakurai Kensuke
Furukawa Shigeru
Katsurada Takehiko
Otagiri Shinsuke
Yamanashi Kana
Nagashima Kazunori
Onishi Reizo
Yagisawa Keiji
Nishimura Haruto
Ito Takahiro
Maemoto Atsuo
Sakamoto Naoya
|
|
|
Abstract
|
|
|
Background/Aims: Inflammatory bowel disease (IBD) patients frequently have zinc deficiency. IBD patients with zinc deficiency have higher risks of IBD-related hospitalization, complications, and requiring surgery. This study aimed to examine the effectiveness of zinc acetate hydrate (ZAH; Nobelzin) in IBD patients with zinc deficiency.
Methods: IBD patients with zinc deficiency who received ZAH from March 2017 to April 2020 were registered in this two-center, retrospective, observational study. Changes in serum zinc levels and disease activity (Crohn’s Disease Activity Index [CDAI]) before and after ZAH administration were analyzed.
Results: Fifty-one patients with Crohn’s disease (CD, n = 40) or ulcerative colitis (UC, n = 11) were registered. Median serum zinc level and median CDAI scores significantly improved (55.5-91.0 μg/dL, P<0.001; 171.5-129, P<0.001, respectively) in CD patients 4 weeks after starting ZAH administration. Similarly, median serum zinc levels and CDAI scores significantly improved (57.0-81.0 μg/dL, P<0.001; 177-148, P=0.012, respectively) 20 weeks after starting ZAH administration. Similar investigations were conducted in groups where no treatment change, other than ZAH administration, was implemented; significant improvements were observed in both serum zinc level and CDAI scores. Median serum zinc levels in UC patients 4 weeks after starting ZAH administration significantly improved from 63.0 to 94.0 μg/dL (P=0.002), but no significant changes in disease activity were observed. One patient experienced side effects of abdominal discomfort and nausea.
Conclusions: ZAH administration is effective in improving zinc deficiency and may contribute to improving disease activity in IBD.
|
|
|
KEYWORD
|
|
|
Inflammatory bowel diseases, Zinc deficiency, Ulcerative colitis, Crohn disease, Zinc acetate
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|
|